- Home
- TFIN vs IMCR Comparison
TFIN vs IMCR Comparison
Compare TFIN & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TFIN
- IMCR
- Stock Information
- Founded
- TFIN 1981
- IMCR 2008
- Country
- TFIN United States
- IMCR United Kingdom
- Employees
- TFIN N/A
- IMCR N/A
- Industry
- TFIN Major Banks
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TFIN Finance
- IMCR Health Care
- Exchange
- TFIN Nasdaq
- IMCR Nasdaq
- Market Cap
- TFIN 1.5B
- IMCR 1.8B
- IPO Year
- TFIN N/A
- IMCR 2021
- Fundamental
- Price
- TFIN $57.10
- IMCR $33.42
- Analyst Decision
- TFIN Hold
- IMCR Buy
- Analyst Count
- TFIN 4
- IMCR 8
- Target Price
- TFIN $70.75
- IMCR $57.00
- AVG Volume (30 Days)
- TFIN 192.2K
- IMCR 288.3K
- Earning Date
- TFIN 10-15-2025
- IMCR 11-05-2025
- Dividend Yield
- TFIN N/A
- IMCR N/A
- EPS Growth
- TFIN N/A
- IMCR N/A
- EPS
- TFIN 0.44
- IMCR N/A
- Revenue
- TFIN $409,227,000.00
- IMCR $356,145,000.00
- Revenue This Year
- TFIN $12.07
- IMCR $29.67
- Revenue Next Year
- TFIN $14.74
- IMCR $11.12
- P/E Ratio
- TFIN $132.23
- IMCR N/A
- Revenue Growth
- TFIN 2.49
- IMCR 26.78
- 52 Week Low
- TFIN $42.90
- IMCR $23.15
- 52 Week High
- TFIN $110.58
- IMCR $39.33
- Technical
- Relative Strength Index (RSI)
- TFIN 43.12
- IMCR 44.20
- Support Level
- TFIN $56.87
- IMCR $35.33
- Resistance Level
- TFIN $60.27
- IMCR $36.76
- Average True Range (ATR)
- TFIN 2.43
- IMCR 1.46
- MACD
- TFIN -0.55
- IMCR -0.12
- Stochastic Oscillator
- TFIN 15.31
- IMCR 24.65
About TFIN Triumph Financial Inc.
Triumph Financial Inc is a financial holding company. The company has four reportable segments namely Banking, Factoring, Payments, and Intelligence. The Banking segment includes the operations of TBK Bank. The Factoring segment includes the operations of Triumph Financial Services with revenue derived from factoring services, The Payments segment includes the operations of TBK Bank's TriumphPay division which provides a presentment, audit and payment solution to Shipper, Broker, and Factor clients in the trucking industry and The Intelligence segment includes to turn the over-the-road trucking data collected through the services into actionable insights for their customers.
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.